SCHEMBL23294571

SCHEMBL23294571

Cc1ccccc1-c1nn[nH]c1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HAO1 Q9UJM8 5/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MCL1 Q07820 2/20 0.40
▸ MYC P01106 1/20 0.40
▸ RPA1 P27694 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ KDM5A P29375 1/20 0.39
▸ KDM4C Q9H3R0 1/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ SMO Q99835 1/20 0.38
▸ NR1H4 Q96RI1 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ ALPL P05186 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ RXRA P19793 1/20 0.37
▸ RXRB P28702 1/20 0.37
▸ RXRG P48443 1/20 0.37
▸ NOTUM Q6P988 1/20 0.37
▸ DCUN1D1 Q96GG9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26849394 0.87 GAA (0.40) HPGDGAASMOKDM4EALDH1A1
SCHEMBL23294646 0.83 GAA (0.38) HPGDGAAKDM4EALDH1A1ALPL
SCHEMBL31172948 0.82 HAO1 (0.40) HAO1HPGDKDM4EALDH1A1ALPL
SCHEMBL17866354 0.82 HAO1 (0.40) HAO1HPGDKDM4EALDH1A1ALPL
SCHEMBL23294662 0.81 HAO1 (0.42) HAO1HPGDKDM4EALDH1A1ALPL
SCHEMBL29852207 0.81 HAO1 (0.42) HAO1HPGDKDM4EALDH1A1ALPL
SCHEMBL15946998 0.78 KDM4E (0.46) HAO1HPGDGAAKDM4EALDH1A1
SCHEMBL29244334 0.76 GAA (0.44) HPGDGAAKDM4EALDH1A1NOTUM
Hydrochloric Acid SCHEMBL3527570 0.76 KDM4E (0.44) HAO1HPGDGAAKDM4EALDH1A1
SCHEMBL5601860 0.75 GAA (0.47) HPGDGAAKDM4EALDH1A1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051667-B1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS LILAC THERAPEUTICS INC (US) 2026-01-28 — — EP disclosed
CN-114929676-B Heterocyclic carboxylate compounds as glycolate oxidase inhibitors 紫丁香疗法有限公司 2025-04-29 — — CN disclosed
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors LILAC THERAPEUTICS INC (US) 2025-02-27 — — US disclosed
US-12168002-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2024-12-17 — — US disclosed
EP-4470538-A2 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
US-20240091200-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors Lilac Therapeutics, Inc. 2024-03-21 — — US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed
EP-4051667-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. (US) 2022-09-07 — — EP disclosed
CN-114929676-A Heterocyclic carboxylate compounds as glycolate oxidase inhibitors 紫丁香疗法有限公司 2022-08-19 — — CN disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 — — US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 — — US disclosed
WO-2021086874-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS GyanRx Sciences, Inc. (US) 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240091200-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors UGDH, PGD, PNPO HAO1 46/4885HPGD 78/4885MCL1 2476/4885
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO HAO1 46/4885HPGD 78/4885MCL1 2476/4885
US-12168002-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO HAO1 46/4885HPGD 78/4885MCL1 2476/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO HAO1 46/4885HPGD 78/4885MCL1 2476/4885
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors GLS, DUOX1, HAO1 HAO1 3/4885HPGD 44/4885MCL1 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback